- Report
- February 2026
- 279 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 285 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 382 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 386 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 382 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 211 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 367 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 291 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 193 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 224 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 291 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 183 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 179 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 193 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 590 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- January 2026
- 192 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 182 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- October 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells.
CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors.
CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more